Cargando…

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations

The T790M mutational basis of treatment failure, following treatment via alteration of the epidermal growth factor receptor (EGFR) pathway, is a well-known anomaly in patients with non-small cell lung cancer (NSCLC). The T790M mutation activates the kinase domain, causing tyrosine kinase inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zang, Shu-Zhi, Yang, Yan-Rong, Zhao, Sha-Sha, Li, Yun-Xia, Gao, Xin-Yuan, Zhong, Chun-Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443239/ https://www.ncbi.nlm.nih.gov/pubmed/28565760 http://dx.doi.org/10.3892/etm.2017.4168

Ejemplares similares

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
por: Xiang, Mingli, et al.
Publicado: (2013)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
por: Liu, Yang, et al.
Publicado: (2017)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
por: Mäkinen, Netta, et al.
Publicado: (2021)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
por: Haratake, Naoki, et al.
Publicado: (2020)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
por: Pan, Guoqiang, et al.
Publicado: (2021)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
por: Li, Hang, et al.
Publicado: (2014)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko, Brian, et al.
Publicado: (2017)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
por: Kimura, Hideharu, et al.
Publicado: (2019)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
por: Yamane, Hiromichi, et al.
Publicado: (2013)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
por: Kim, Ji Yeon, et al.
Publicado: (2018)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
por: Fawwaz, Muammar, et al.
Publicado: (2021)

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
por: Iwama, Eiji, et al.
Publicado: (2015)

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR
por: Silveira, Catarina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ej8249tl11asepgam10lp3h4m8